Latest From Dermira Inc.
Sanofi/Regeneron’s pioneering biologic, dupilumab, is growing its potential market before the advent of competing molecules. An EU approval extension, allowing use in adolescents as well as in adults, and positive Phase III results in children aged six to 11 years with severe atopic dermatitis, should help.
CEO Peter Guenter’s focus on first- and best-in-class looks like the right strategy as Spanish pharma builds critical mass in dermatology.
Public Company Edition: Jefferies report notes robust IPO market, but SVB Leerink predicts a financing slowdown. Also, Mirati raises cash for KRAS programs after Amgen's ASCO data and a strategic shift results in job cuts at ImmunoGen.
Pfizer follows Lilly as the second company to report positive top-line Phase III results in AD for a JAK inhibitor. Safety is a key concern for the class, but Pfizer did not provide any details about abrocitinib's side effects.
- Large Molecule
- Topical Delivery
- Specialty Pharmaceuticals
- Drug Delivery
- Therapeutic Areas
- Skintelligence Inc.
- North America
- Parent & Subsidiaries
- Dermira Inc.
- Senior Management
Thomas G Wiggans, CEO
Andrew Guggenhime, CFO
Eugene A Bauer, MD, CMO
Chris Griffith, Chief Business & Strategy Officer
Luis Pena, PhD, Chief Dev. Officer
Lori Lyons-Williams, Chief Commercial Officer
- Contact Info
Phone: (650) 421-7200
275 Middlefield Rd.
Menlo Park, CA 94025
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.